Jim Simons’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-887,740
| Closed | -$2.36M | – | 4109 |
|
|
2024
Q1 | $2.36M | Buy |
887,740
+312,761
| +54% | +$774K | ﹤0.01% | 1925 |
|
|
2023
Q4 | $1.36M | Buy |
574,979
+69,023
| +14% | +$122K | ﹤0.01% | 2204 |
|
|
2023
Q3 | $708K | Buy |
505,956
+168,156
| +50% | +$404K | ﹤0.01% | 2534 |
|
|
2023
Q2 | $1.02M | Buy |
337,800
+227,300
| +206% | +$876K | ﹤0.01% | 2455 |
|
|
2023
Q1 | $691K | Buy |
110,500
+7,100
| +7% | +$43.3K | ﹤0.01% | 2699 |
|
|
2022
Q4 | $631K | Buy |
103,400
+2,900
| +3% | +$23.6K | ﹤0.01% | 2808 |
|
|
2022
Q3 | $1.2M | Buy |
100,500
+4,900
| +5% | +$64.1K | ﹤0.01% | 2384 |
|
|
2022
Q2 | $1.21M | Buy |
95,600
+71,700
| +300% | +$667K | ﹤0.01% | 2585 |
|
|
2022
Q1 | $269K | Buy |
+23,900
| New | +$263K | ﹤0.01% | 3519 |
|
|
2021
Q4 | – | Sell |
-23,358
| Closed | -$538K | – | 4310 |
|
|
2021
Q3 | $538K | Sell |
23,358
-12,542
| -35% | -$273K | ﹤0.01% | 2860 |
|
|
2021
Q2 | $836K | Buy |
+35,900
| New | +$913K | ﹤0.01% | 2760 |
|
Jim Simons's KNTE Position: Q2 2024 in Review
Jim Simons sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 887,740 shares — an estimated $2.36M sold.
Jim Simons first reported a position in KNTE in Q2 2021 and held it in 11 quarters. The position peaked at $2.36M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Jim Simons reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Jim Simons sold 887,740 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $2.36M.
- Jim Simons first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2021 and held it in 11 quarters.
- Jim Simons's Kinnate Biopharma Inc. Common Stock position peaked at $2.36M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.